Search
Search titles only
By:
Search titles only
By:
Log in
Register
Search
Search titles only
By:
Search titles only
By:
Menu
Install the app
Install
Forums
New posts
All threads
Latest threads
New posts
Trending threads
Trending
Search forums
What's new
New posts
New ads
New profile posts
Latest activity
Free Ads
Latest reviews
Search ads
Members
Current visitors
New profile posts
Search profile posts
Contact us
Latest ads
Ad icon
ZTE MF283U 4G Unlocked Router (Used)
ayanthamaxi
Updated:
Sunday at 8:26 PM
ලංකාවේ හොඳම උපකාරක පන්ති සහ ගුරුවරුන් එකම තැනකින් - TopTuition.lk
dulithapathum
Updated:
Saturday at 8:07 AM
Colombo
RidhMathraa ’26 🎶✨
Tmadhusanka
Updated:
Wednesday at 11:58 PM
Ad icon
Colombo
PXN V10 Pro Direct Drive Racing Wheel (Under Warranty)
Abdur Rahman
Updated:
Wednesday at 10:23 PM
Ad icon
USDT ණය සේවාව - USDT Loan Service
පුරවැසියා
Updated:
Wednesday at 4:54 PM
Electronics
Vehicles
Property
Search
Reply to thread
Forums
General
ElaKiri Talk!
New Drug for Obesity from Syntis-Bio.
Get the App
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Message
<blockquote data-quote="imhotep" data-source="post: 30735059" data-attributes="member: 562115"><p><strong>A new once-daily pill may raise the bar for weight loss meds.</strong></p><p></p><p>Ozempic, Mounjaro and similar drugs that mimic the GLP-1 hormone the body naturally produces after eating can cause significant weight loss, <strong>but a potential side effect is loss of lean muscle mass.</strong></p><p></p><p>The makers of the experimental drug SYNT-101 claim it <strong>mimics the effects of gastric bypass surgery while preserving lean muscle mass better than GLP-1 drugs.</strong></p><p></p><p>SYNT-101 forms a synthetic film on the surface of the <em>s</em>mall intestine, shifting nutrient exposure to the lower intestine to promote a feeling of fullness. The lining is designed to work for up to 24 hours before it’s naturally cleared from the body. </p><p></p><p>In a new first-in-human study, seven women and two men between the ages of 24 and 53, who were not considered obese, took varying doses of SYNT-101 in liquid form.</p><p>Imaging confirmed that the coating formed across the upper small intestine, and tissue samples showed that SYNT-101 was safely expelled within 24 hours.</p><p>Further testing showed the participants had normal liver function and lower glucose absorption.</p><p>No serious side effects were reported.</p><p></p><p>Weight loss was not tracked for this study, but the researchers said the results reflected reduced food consumption. In rodent studies, SYNT-101 produced weight loss of 1% a week for six weeks while preserving 100% of lean muscle mass.</p><p>During the 10 days following treatment, liver enzymes including aspartate transaminase (AST), alanine transaminase (ALT) and bilirubin remained stable for each participant, consistent with normal liver functioning.</p><p></p><p>Additionally, gastrointestinal tolerance was excellent, with no changes noted in the Gastrointestinal Symptom Rating Scale (GSRS), and all participants reported an average pain rating of 0.</p><p></p><p>Importantly, glucose tolerance tests revealed delayed uptake of glucose following SYNT-101 treatment. At 30 and 60 minutes, glucose absorption was far lower than in untreated patients, by roughly 35% and 21% respectively. This delay suggests that absorption occurs later in the intestine, as expected, rather than in the coated region of the duodenum.</p></blockquote><p></p>
[QUOTE="imhotep, post: 30735059, member: 562115"] [B]A new once-daily pill may raise the bar for weight loss meds.[/B] Ozempic, Mounjaro and similar drugs that mimic the GLP-1 hormone the body naturally produces after eating can cause significant weight loss, [B]but a potential side effect is loss of lean muscle mass.[/B] The makers of the experimental drug SYNT-101 claim it [B]mimics the effects of gastric bypass surgery while preserving lean muscle mass better than GLP-1 drugs.[/B] SYNT-101 forms a synthetic film on the surface of the [I]s[/I]mall intestine, shifting nutrient exposure to the lower intestine to promote a feeling of fullness. The lining is designed to work for up to 24 hours before it’s naturally cleared from the body. In a new first-in-human study, seven women and two men between the ages of 24 and 53, who were not considered obese, took varying doses of SYNT-101 in liquid form. Imaging confirmed that the coating formed across the upper small intestine, and tissue samples showed that SYNT-101 was safely expelled within 24 hours. Further testing showed the participants had normal liver function and lower glucose absorption. No serious side effects were reported. Weight loss was not tracked for this study, but the researchers said the results reflected reduced food consumption. In rodent studies, SYNT-101 produced weight loss of 1% a week for six weeks while preserving 100% of lean muscle mass. During the 10 days following treatment, liver enzymes including aspartate transaminase (AST), alanine transaminase (ALT) and bilirubin remained stable for each participant, consistent with normal liver functioning. Additionally, gastrointestinal tolerance was excellent, with no changes noted in the Gastrointestinal Symptom Rating Scale (GSRS), and all participants reported an average pain rating of 0. Importantly, glucose tolerance tests revealed delayed uptake of glucose following SYNT-101 treatment. At 30 and 60 minutes, glucose absorption was far lower than in untreated patients, by roughly 35% and 21% respectively. This delay suggests that absorption occurs later in the intestine, as expected, rather than in the coated region of the duodenum. [/QUOTE]
Insert quotes…
Verification
Payakata winadi keeyak tibeda?
Post reply
Top
Bottom